Healthy controls | Allergic rhinitis | Allergic asthma β2-agonists on demand | Allergic asthma ICS-treatment | |
---|---|---|---|---|
Number in group | 21 | 13 | 16 | 16 |
Mean age years (range) | 24 (21–29) | 25 (22–34) | 24 (18–32) | 24 (19–41) |
Gender (male:female) | 12:9 | 6:7 | 8:8 | 8:8 |
FEV1 (% predicted) | 98 ± 15 | 97 ± 15 | 99 ± 15 | 93 ± 8 |
PC20 (mg/mL)a | Not assessed | >8.0 | 2.7 ± 1.8 | >8.0 |
Skin prick test to pollens | Negative | Positive | Positive | Positive |
SM eosinophils (cells/mlx104)a | 0.0 (0.0-0.0) | 0.4 (0.0-1.2) | 0.1 (0.0-1.2) | 0.0 (0.0-0.3) |
SM mast cells (cells/mlx104) | 19 (11–27) | 16 (14–28) | 27 (18–31) | 16 (12–22) |
SM neutrophils (cells/mlx104)a | 61 (30–78) | 57 (26–102) | 47 (19–97) | 98 (75–124) |